Medicare must recognize obesity as a chronic disease and provide coverage for the treatments that can help those who struggle ...
Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
By now, many people have heard that a diet packed with ultraprocessed foods is not good for us. They have been linked to<a ...
A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming ...
Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and ...
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...
A study from the University of Kansas reveals that most U.S. infant formulas contain mainly added sugars instead of the ...